Issue link: https://www.e-digitaleditions.com/i/1491587
Inhalation FEBRUARY 2023 31 5. Mani Ordoubadi, Florence K. A. Gregson, Hui Wang, Mark Nicholas, Sandra Gracin, David Lechuga-Ballesteros, Jonathan P. Reid, Warren H. Finlay and Reinhard Vehring. On the particle for- mation of leucine in spray drying of inhalable micrparticles. International Journal of Pharmaceu- tics (2021): 592. Maureen Kadleck, BSE, is Group Lead Inhalation and Joseph Churchman, BS, is a Scientist III Inhala- tion, Lonza AG, Bend, Oregon, US. Bryce Beverlin II, PhD, is CEO, Quench Medical, Inc., St. Paul, MN, US. Corresponding author: Maureen Kadleck, Lonza AG, 64550 Research Road, Bend, OR, 97703, US, www.lonza.com/small-molecules/oral-drug-products/ dry-powder-inhalation. these programs includes manufacturing robustness and potential clinical supplies. Along with the potential for improving lung cancer survival rates, EEG therapies o er the potential for greater e cacy in treating a broad range of lung dis- eases while reducing side e ects. e EEG formu- lations may well be the logical leap in drug delivery necessary to open new markets for previously unfea- sible or ine ective therapies. References 1. Bryce Beverlin II, Michael Hindle, P. Worth Longest, Matthew Ferguson, Philip J. Kuehl, Anita Lopez, Derek Montoya, Ariana Anjier and Nancy B. Gordon. Targeting lung tumors using a novel inhaled excipient enhanced growth gemcitabine dry powder formulation. Respiratory Drug Delivery 2022. Florida, US, 2022. 123. 2. Michael Hindle, P. Worth Longest. Condensa- tional growth of combination drug-excipient sub- micrometer particles for targeted high-e ciency pulmonary delivery: Evaluation of formulation and delivery device. Journal of Pharmacy and Pharma- cology (2012): 64: 1254-1263. 3. Abhishek Singh, Guy Van den Mooter. Spray drying formulation of amorphous solid disper- sions. Advanced Drug Delivery Reviews (2016): 100: 27-50. 4. Yoen-Ju Son, P. Worth Longest, Geng Tian, Michael Hindle. Evaluation and modi cation of commercial dry powder inhalers for the aerosoliza- tion of a submicrometer excipient enhanced growth formulation. European Journal of Pharmaceutical Sciences (2013): 49: 390-339. Figure 7 Gemcitabine formulation comparison after 1 month, via ne particle fraction captured by FSI screening. Standard deviations are shown in black and indicate good agreement between samples. Fine Particle Fraction % 100 90 80 70 60 50 40 30 20 10 0 40/40/20 Gem/NaCl/Leu 50/20/30 Gem/NaCl/Leu 55/20/25 Gem/NaCl/Leu 60/20/20 Gem/NaCl/Leu 40/40/20 Gem/Mann/Leu